In his weekly clinical update, Dr. Griffin discusses the how the pandemic influenced the healthcare job market before he reviews most recent statistics on the circulation of respiratory syncytial virus, influenza virus and SARS-CoV-2 virus, including all circulating variants in the US, discusses the safety of the prefusion RSV vaccine, if high or moderate dose of the quadrivalent influenza vaccine is better for protection against hospitalization, summarizes the new WHO COVID guidelines, revisits how to prevent pathogen transmission in healthcare setting, the under use of COVID oral antiviral and what occurs in persistently SARS-CoV-2 infected cells in culture after antiviral treatment, continues to dispel the myth of viral rebound, how to pay for paxlovid, when to use steroids and the benefits of convalescent plasma, how inflammatory markers change correlate with death when in ICU and if cognitive slowing is part of long COVID-19.

Click arrow to play
Download TWiV 1084 (32 MB .mp3, 44 min)
Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email

Become a patron of TWiV!

Links for this episode

• Do you want a job in healthcare? (JAMA) 1:46
• Respiratory disease surveillance (CDC) 4:20
• RSV surveillance (CDC)
• RSV national trend (CDC)
• Efficacy and safety of RSV vaccine after 2 seasons (CID) 4:54
• High vs moderate dose of quadrivalent influenza vaccine (CMI) 8:06
• Influenza/flu surveillance (CDC) 10:43
• Influenza/flu map (CDC)
• COVID-19  hospital admissions (CDC)
• COVID-19 national trend (CDC) 11:35
• COVID-19 wastewater testing (biobot)
• Variant tracker (CDC)
• Variant hospital admissions (CDC)
• WHO COVID guidance (WHO) 12:30
• Thoughts on COVID guidance (CIDRAP) 12:37
• Update on how to prevent pathogen transmission in healthcare settings (CDC) 17:37
• Underuse of antiviral drugs against COVID-19 (MMWR) 21:20
• Revisiting tissue culture cells persistently infected following antiviral therapy (bioRxiv) 23:51
• To rebound or to not rebound (MMWR)
• Know your COVID-19 tools (ESMED)
• How to pay for Paxlovid (PAXCESS)
• Molnupiravir safety and efficacy (JMV)
• Convalescent plasma recommendation for immunocompromised (IDSociety)
• Steroids,dexamethasone at the right time (OFID)
• Anticoagulation guidelines (hematology.org)
• Changes in inflammatory markers and death correlation when in ICU (Cytokine) 30:15
• Long COVID & cognitive slowing? (eClinicalMedicine) 31:54
• Contribute to our ASTMH fundraiser at PWB 35:50
• Letters read on TWiV 1084 36:31
• Dr. Griffin’s COVID treatment summary (pdf)
• Timestamps by Jolene. Thanks!

Intro music is by Ronald Jenkees

Send your questions for Dr. Griffin to daniel@microbe.tv

In his weekly clinical update, Dr. Griffin reviews most recent statistics on the circulation of respiratory syncytial virus, influenza virus and SARS-CoV-2 virus, including all circulating variants in the US, before discussing viral transmission to adults in healthcare setting, the recently EUA approved protein based COBREVAX vaccine, reviews quarantine guidelines, the use of simnotrelivr for mild to moderate COVID-19, how viral RNA may persist in your cell culture dish following antiviral therapy, continues to dispel the myth of viral rebound, how to pay for Paxlovid, , when to use steroids and the benefits of convalescent plasma, how Paxlovid may prevent long COVID and how complement dysfunction may lead to thromboinflammation during long COVID.

Click arrow to play
Download TWiV 1082 (39 MB .mp3, 54 min)
Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email

Become a patron of TWiV!

Links for this episode

• Articles and graphs cited in TWIV CU 1080
• Respiratory  disease surveillance (CDC)
• RSV surveillance  (CDC) 2:30
• RSV national trend (CDC)
• Influenza/flu surveillance (CDC) 5:05
• Influenza/flu map (CDC)
• COVID-19  hospital admissions (CDC)
• COVID-19 national trend (CDC) 8:16
• COVID-19 wastewater testing (biobot)
• Variant tracker (CDC)
• Variant hospital admissions (CDC)
• Transmission in healthcare setting (CID) 10:22
• COBREVAX EUA (Texas Children’s Hospital) 17:42
• Quarantine/isolation guidelines (CDC)
• Simnotrelvir for mild to moderate disease in adults (NEJM) 19:59
• Are your tissue culture cells persistently infected following antiviral therapy (bioRxiv) 24:33
• Structural biology of antivirals for SARS-CoV-2 (Signal Tranduction and Targeted Therapy)
• To rebound or to not rebound (MMWR)
• Know your COVID-19 tools (ESMED)
• How to pay for Paxlovid (PAXCESS)
• Remdesivir for immunocompromised during variant waves (CID) 35:02
• Molnupiravir safety and efficacy (JMV)
• Convalescent plasma recommendation for immunocompromised (IDSociety)
• Steroids,dexamethasone at the right time (OFID)
• Anticoagulation guidelines (hematology.org)
• Patients, experts, Congress…..long COVID oh my! (CIDRAP) 39:26
• Does paxlovid prevent long COVID? (CIDRAP) 41:13
• Persistent complement with thromboinflammation in long COVID (Science) 42:15
• Contribute to our MicrobeTV fundraiser at PWB 47:28
• Letters read on TWiV 1082 48:15
• Dr. Griffin’s COVID treatment summary (pdf)
• Timestamps by Jolene. Thanks!

Intro music is by Ronald Jenkees

Send your questions for Dr. Griffin to daniel@microbe.tv

In his weekly clinical update, Dr. Griffin reviews most recent statistics on the circulation of respiratory syncytial virus, influenza virus and SARS-CoV-2 virus in the US before discussing vaccine effectiveness in children and adolescents, how the pandemic impacted the socioemotional development of infants and toddlers, continues to dispel the myth of viral rebound, how to pay for Paxlovid, reviews quarantine guidelines, when to use steroids and the benefits of convalescent plasma, examines the role of immune aberrations in long COVID and how vaccination may protect against developing long COVID.

Click arrow to play
Download TWiV 1078 (24 MB .mp3, 34 min)Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email

Become a patron of TWiV!

Links for this episode

• Respiratory disease surveillance (CDC)
• RSV surveillance (CDC) 2:09
• RSV national trend (CDC)
• Influenza/flu surveillance (CDC) 2:50
• Influenza/flu map (CDC)
• COVID-19  hospital admissions (CDC)
• COVID-19 national trend (CDC) 3:33
• COVID-19 wastewater testing (biobot) 4:25
• Variant tracker (CDC)
• Remember when COVID was bad? (Wired) 4:55
• Children and adolescents hospitalized with SARI (Pediatrics) 5:31
• COVID-19 vaccines are effective for adolescents (Pediatrics) 6:55
• Vaccine effectiveness against long COVID in children (Pediatrics) 8:40
• Infant and toddler socioemotional development in the pandemic (JAMA) 9:05
• Quarantine/isolation guidelines (CDC)
• Should I take Paxlovid? (NY Times) 11:48
• What is this about Paxlovid rebound? (CDC) 13:15
• Rebound is NOT the early inflammatory phase (ESMED)
• How to pay for Paxlovid (PAXCESS) 14:25
• Molnupiravir safety and efficacy (JMV)
• Convalescent plasma recommendation for immunocompromised (IDSociety)
• Steroids, dexamethasone at the right time (OFID)
• Anticoagulation guidelines (hematology.org) 16:51
• T cell dysregulation inflammation and uncoordinated adaptive immune response, Long COVID oh my (Nat Imm) 17:47
• Vaccine effectiveness against long COVID (CIDRAP) 23:04
• Prevention of long COVID by vaccines (Antimicrobial-stewardship and healthcare)
• Sex and gender relationship with long COVID (Eurosurveillance)
• Are all vaccines equal in preventing Long COVID? (Lancet)
• Vaccine naïve individuals, Long COVID and vaccination (medRxiv)
• Contribute to our MicrobeTV fundraiser at PWB 28:41
• Letters read on TWiV 1080 29:05
• Dr. Griffin’s COVID treatment summary (pdf)
• Timestamps by Jolene. Thanks!

Intro music is by Ronald Jenkees

Send your questions for Dr. Griffin to daniel@microbe.tv

In his weekly clinical update, Dr. Griffin reviews recent measles outbreaks, prequalification of nOPV2 by the WHO and most recent statistics on the circulation of respiratory syncytial virus, influenza virus and SARS-CoV-2 virus in the US before discussing COVID-19 deaths linked to SNPs in C-reactive protein, spread of recent viral variants, how early vaccination reduced hospitalization of those infected with XBB.1.5, reviewed quarantine guidelines, how oral antivirals reduce hospitalizations, dissociation of antiviral treatment from infection rebound, and long COVID, deaths due to administration of hydroxychloroquine, muscle abnormalities and extreme fatigue in individuals with long COVID-19 and how the economics of where you live make long COVID-19 more severe.

Click arrow to play
Download TWiV 1078 (51 MB .mp3, 71 min)Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email

Become a patron of TWiV!

Links for this episode

• A national measles campaign (CDC)
• A nation of measles (CDC)
• The measles unvaccinated in NY (CNN)
• Philadelphia’s measles story (Phila gov) 4:18
• January’s measles outbreak (CNN)
• Prequalify of nOPV2 by WHO (GPEI) 7:21
• Did you prequalify for the novel poliovirus vaccine (CIDRAP)
• Respiratory  disease surveillance (CDC) 10:19
• RSV surveillance  (CDC)
• RSV national trend(CDC)
• Influenza/flu surveillance (CDC) 10:45
• Influenza/flu map (CDC)
• COVID-19  hospital admissions (CDC)
• COVID-19 national trend (CDC) 11:56
• COVID-19 wastewater testing (biobot)
• Death rate and C-reactive protein SNPs and COVID-19 (Scientific Reports)
• Variant tracker (CDC) 14:29
• Tracking variant hospitalizations (CDC)
• Early vaccination against XBB.1.5 hospitalization (Eurosurveillance) 22:30
• Vaccination dashboard (Netherlands) 26:04
• Quarantine/isolation guidelines (CDC)
• Antiviral gap among the non-hospitalized high risk adults (CID) 27:32
• Oral antivirals prevent hospitalization (medRxiv) 28:58
• Rebound with and without oral antivirals (MMWR) 31:35
• Randomized rebound trials (MMWR) 32:18
• Know your COVID-19 tools (ESMED) 32:39
• The PASC-paxlovid relationship (JAMA) 33:20
• Molnupiravir safety and efficacy (JMV) 33:35
• Convalescent plasma remmendation for immunocompromised (IDSociety) 33:40
• Fluvoxamine for COVID-19 outpatient (RMV) 33:47
• Death by hydroxychloroquine (Biomedicine & Pharmacotherapy) 37:01
• Steroids, dexamethasone at the right time (OFID) 41:31
• Anticoagulation guidelines (hematology.org) 42:20
• Doxycycline for prevention of progression of COVID-19 (PLoS One) 42:44
• Muscle abnormalities in long COVID (Nat Comm) 48:01
• Discovery of persistent fatigue in long COVID-19 (Amsterdam Univ Med Crr) 57:08
• IMPACC study post-acute sequelae results (Nat Comm) 58:48
• Double course of long COVID in low income countries (Nat) 1:00:20
• Contribute to our MicrobeTV fundraiser at PWB 1:02:01
• Letters read on TWiV 1078 1:02:35
• Dr. Griffin’s COVID treatment summary (pdf)
• Timestamps by Jolene. Thanks!

Intro music is by Ronald Jenkees

Send your questions for Dr. Griffin to daniel@microbe.tv

In his weekly clinical update, Dr. Griffin highlights global circulation of Mpox virus, reviews the most recent statistics on the circulation of respiratory syncytial virus, influenza virus and SARS-CoV-2 virus in the US, and discusses the clinical outcome of hospitalized children under 5 years infected with SARS-CoV-2, the perinatal and neonatal outcomes including adverse effects of SARS-CoV-2 infection and virus transmission in Italy between early 2020 and 2022, the guidelines to improve home ventilation, the safety and efficacy of the oral anti-viral molnupiravir and the use of convalescent plasma as a long term treatment as well as treatment specifically for the immune compromised, the ineffectiveness of antibiotics for treating COVID-19, the association of olfactory dysfunction and the administration of corticosteroids and the safety of the RSV vaccines licensed last year.

Click arrow to play

Download TWiV 1075 (20 MB .mp3, 28 min)

Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email

Become a patron of TWiV!

Links for this episode

• Articles and graphs cited in TWIV CU 1076
• Global mpox circulation (WHO) 1:33
• Mpox in the Americas and Europe (CIDRAP) 1:33
• Respiratory  disease surveillance (CDC)
• RSV surveillance  (CDC)
• RSV national trend (CDC)
• Influenza/flu surveillance  (CDC)
• Influenza/flu map (CDC)
• COVID-19  hospital admissions (CDC)
• COVID-19 national trend (CDC)
• COVID-19 wastewater testing (biobot) 4:16
• Vaccine-Eligible Children Under-5 Years (PIDJ) 4:32
• Pre-school cohort vaccination rate (CIDRAP)
• Perinatal transmission and neonatal outcomes (IJID) 6:39
• Adverse maternal and neonatal effect (dgalerts)
• Ventilation home improvements (CDC) 8:35
• Quarantine/isolation guidelines (CDC)
• Molnupiravir safety and efficacy (JMV)
• Convalescent plasma remmendation for immunocompromised (IDSociety)
• Corticosteroids in SARS-CoV-2
• Anticoagulation guidelines (hematology.org) 9:43
• Corticosteroids induced olfactory dysfunction (PLoS One) 10:14
• Convalescent Plasma Therapy: Long Term Implications (OFID) 13:43
• Preventing RSV infection by vaccination (MMWR)
• Antivirals and chronic kidney disease (CID)
• Early administraton of molnupiravir versus ritonavir-boosted nirmatrelvir (Lancet Infectious Diseases)
• Contribute to our MicrobeTV fundraiser at PWB 15:58
• Letters read on TWiV 1076 16:18
• Dr. Griffin’s COVID treatment summary (pdf)
• Timestamps by Jolene. Thanks!

Intro music is by Ronald Jenkees

Send your questions for Dr. Griffin to daniel@microbe.tv